SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : analysts and calls -- ML
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (44)9/17/2003 12:07:29 PM
From: Icebrg  Read Replies (1) of 238
 
7:57AM NPS Pharm target raised to $46 at Merrill Lynch (NPSP) 30.90: Merrill Lynch raises their target to $46 from $37, as firm believes that investors have ignored recent sales strength of LLY's osteoporosis drug Forteo (which is in the same class as NPSP's Preos) and that Forteo sales trends indicate a major mkt opportunity for Preos; firm also expects positive data at ASBMR this weekend; finally, firm believes that yesterday's weakness due to concerns about the Cinacalcet launch expected in 2H04 creates an opportunity to buy the stock in front of multiple catalysts during the next 6-9 months.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News